Regeneron (NY, USA) has finally brought alirocumab (trade name Praluent) to the finish line with collaborator Sanofi, today announcing that the European commission has granted its hypercholesterolemia drug a marketing license for the EU. Having already been approved by the FDA in July, this completes Praluent’s launch into the Western pharma market.
New-York based Regeneron (US) has had a long-lived and healthy collaboration with France’s Sanofi since 2007, sharing monoclonal antibody research for R&D in several fields. Now, the pair’s latest success lies in their cardiovascular targeted drug alirocumab (Praluent) which has been developed to treat hypercholesterolemia.
Praluent (alirocumab) is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor which reduces the amount of low-density cholesterol produced in the liver. Marketed to the US for patients who are also taking statins, the EU license permits marketing of Praluent to the same demographic. It has also been developed for sufferers of primary hypercholesterolemia (familial and non-familial types), again in conjunction with dietary adjustments and statin use. The market is expected to be huge,